Nectin-4 ligands
Novel peptide ligands with improved binding affinity and reduced oxidation susceptibility are developed for PET and SPECT imaging, addressing the limitations of current radioligands by enhancing tumor uptake and imaging efficacy.
Patent Information
- Application Number
- PCT/DE2026/100545
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-07
- Filing Date
- 2026-04-29
- Publication Date
- 2026-11-12
AI Technical Summary
Current radioligands targeting Nectin-4 for PET and SPECT imaging exhibit moderate binding affinity, susceptibility to oxidation, and yield undesired oxidation products during synthesis and radiolabeling, leading to reduced efficacy and efficiency in imaging and tumor uptake.
The compounds are peptide-based and designed to target tumor-associated Nectin-4 for the functional characterization of tumor diseases and can be labeled with radionuclides that enable non-invasive molecular imaging, particularly using PET.
The novel peptide ligands demonstrate enhanced binding affinity and reduced susceptibility to oxidation, leading to improved tumor uptake and imaging efficacy.
Smart Images

Figure DE2026100545_12112026_PF_FP_ABST
Abstract
Description
Description Nectin-4 ligands
[0001] The invention relates to peptide-based Nectin-4 ligands, in particular radiolabeled Nectin-4 ligands. The invention further relates to a process for the production of Nectin-4 ligands. It further relates to the use of Nectin-4 ligands for the production of radiopharmaceuticals.
[0002] Approximately 18,270 people in Germany were diagnosed with invasive bladder cancer (also known as muscle-invasive bladder carcinoma) in 2018, roughly a quarter of whom were women. Around 5,600 people died from the disease (RKI, Center for Cancer Registry Data). Bladder cancer is predominantly urothelial carcinoma, which often occurs simultaneously in various locations within the bladder and urinary tract. Following diagnosis, treatment depends on the stage of the disease and includes surgical removal of the tumor, including removal of the bladder, as well as neoadjuvant and adjuvant chemotherapy (including immunotherapy). For patients with metastatic urothelial carcinoma, the antibody-drug conjugate enfortumab vedotin (“EV”, Padcev) has been approved by the FDA and EMA as a targeted therapy since 2019 and 2022, respectively. The antibody unit of Padcev targets the cell surface protein Nectin-4.After binding, the Nectin-4-EV complex is internalized and the toxin monomethyl auristatin E is released by proteolytic cleavage, which subsequently acts cytotoxically by inhibiting tubulin polymerization. 1 A recent study showed that 72 out of 83 (87%) tumor samples of non-muscle-invasive bladder cancer and 50 out of 86 (58%) tumor samples of muscle-invasive bladder cancer were Nectin-4 positive. 2 These results, along with its low prevalence in healthy tissue and its localization on the cell surface, underline the suitability of Nectin-4 as a biological target for radiolabeled ligands, or radioligands for short. 3
[0003] Following Padcev's work, Bicycle Therapeutics developed the bicyclic toxin conjugate BT8009 (zelenectide pevedotin). While the Linker and M 264576 Registration text.docx The toxin unit is similar to Padcev, the Nectin-4 binding unit is a bicyclic peptide which was identified by phage display and subsequently systematically optimized. 5 - 6 Currently, BT8009 is in clinical phase I / II in patients with solid tumors and elevated Nectin-4 levels, including patients with urothelial neoplasms (clinical study: NCT04561362).
[0004] Little is known about radioligands for Nectin-4. Two studies have investigated antibody-based radioligands for PET (positron emission tomography) imaging, labeled with fluorine-18 or zirconium-89. 7 ) and SPECT (single-photon emission computed tomography labeled with technetium-99m) 8 ). Furthermore, a peptide-based radioligand based on BT8009 (bicyclic radiopeptide conjugate) was reported. 68Ga-N188), in which the linker and toxin units were replaced by the radiometallic chelator DOT A and Gallium-68 was used as a diagnostic radionuclide. 9 ' 10 In addition to preclinical evaluation in mice, the first patients with metastatic urothelial carcinoma and other cancers also underwent PET imaging after injection of 68 Ga-N188 was subjected to clinical trials: NCT05321316 and NCT05593107. Derivatives of Ga-N188 were tested in three recently published studies. 68 Ga-N188 developed and preclinically studied (NOTA-PEG) n -BP, DN68, FZ-NR-1-3). 11 ' 12 ' 13 Modifications were made to the peptide backbone and the chelator unit, and different linkers between the chelator unit and the peptide were tested. Furthermore, the following was also investigated: 18 F-labeled ligands reported (N230-232). 14Structural information on BT8009 as well as N188 and its derivatives is shown in Table 1 below. M 264576 Registration text.docx Table 1
[0005] 68 Despite the positive results in preclinical and clinical studies, Ga-N188 still has clear potential for improvement. Firstly, its binding affinity to Nectin-4 is considered to be in need of improvement (K d =23.7 nM), especially considering the emerging whole-body PET / CT scanners for humans (i.e., large axial field of view (LAFOV) PET / CT). Furthermore, the observed tumor images and, in particular, the resulting tumor-to-muscle and tumor-to-blood ratios can be considered moderately satisfactory. 940It is likely that the latter is also due to the moderate binding affinity of the radioligand to Nectin-4. Radioligands against other tumor antigens, especially those against PSMA and SST2, typically exhibit binding affinities in the single-digit nM range or below. The binding affinities of the NOTA-PEGn-BP compound- M 264576 Anmeldungtext.docxgen also appears to be unchanged. 11 while DN68 with a K d -Value of 0.64 nM is significantly more potent. 12
[0006] From a (radio)chemical perspective, all known radioligands share another disadvantage. Similar to BT8009, these compounds contain a methionine residue at position 4 of the bicyclic core. Methionine residues exhibit a certain susceptibility to oxidation, which oxidizes the methyl sulfide group to the corresponding methyl sulfoxide group (Figure 2A). 15This can result in undesired byproducts during the synthesis of non-radioactive peptides and also during radiolabeling. In the case of peptide synthesis, this leads to yield losses, and in the case of radiolabeling, to reduced radiochemical purity. Furthermore, oxidation can lead to altered binding behavior with the corresponding protein. 15
[0007] It is therefore desirable to develop novel peptide ligands that target tumor-associated Nectin-4 for the functional characterization of tumor diseases and can be labeled with radionuclides that enable non-invasive molecular imaging, particularly using PET. Furthermore, these peptide ligands should possess greater binding affinity and improved tumor uptake, as well as be less susceptible to oxidation. In particular, high yields, low energy consumption, and the use of cost-effective raw materials should be achieved.
[0008] The object of the invention is to eliminate the disadvantages of the prior art. In particular, peptide ligands exhibiting the aforementioned properties are to be specified.
[0009] This problem is solved by the features of claims 1, 8, 9, 11 and 12. Advantageous embodiments of the inventions result from the features of the dependent claims.
[0010] According to the invention, a compound of the general formula IM 264576 application text.docx (Formula 1) provided for, whereby Y is; X is selected from the group consisting of O, Se and CH2; D 1-Naphthyl (Dl) or 2-Naphthyl (D2) is; L is selected from the group consisting of M 264576 Registration text.docx M 264576 Registration text.docx R 1 selected from the group consisting of H, F, Cl, Br, I, -CF3, -CH3, -OH and -OCH3; R 2 -OH or -NH2 is; Z CH or N is; M 264576 Registration text.docxm 0 or 1 is; n 0 or 1 is and p is an integer between 1 and 10.
[0011] The compounds of general formula I are peptide ligands, specifically Nectin-4 ligands. It is possible to label these Nectin-4 ligands with a radionuclide, making them suitable for the functional characterization of cancers using positron emission tomography (PET) and single-photon emission computed tomography (SPECT).
[0012] According to the invention, Y in the compounds of general formula I can be Y1, Y2, or Y3. It can further be provided that Y in the compounds of general formula I is Y2. It can be provided that X in the compounds of general formula I is IO, Se, or CH2. XO or CH2 is preferred. XO is particularly preferred.
[0013] According to the invention, A is selected from the group consisting of Al, A2, A3, A4, A5, A6, A7, A8, A9, or A10. Preferably, A is selected from the group consisting of Al, A2, A3, A6, and A9. More preferably, A is selected from the group consisting of Al, A6, and A9. Particularly preferably, A is Al.
[0014] According to the invention, L is selected from the group consisting of LI, L2, L3, L4, L5, L6, L7 and L8. Preferably, L is selected from the group consisting of L2, L3, L5 and L8. Particularly preferred is L2 or L3, and even more preferably L2.
[0015] According to the invention, n can be 0 or 1. Preferably, n is equal to 0.
[0016] According to the invention, m can be 0 or 1. Preferably, m is equal to 1.
[0017] According to the invention, D in the compounds of general formula I can be D1 or D2. Preferably, D is D1. M 264576 Registration text.docx
[0018] According to the invention, a compound of general formula I is preferred in which Y is Y2, XO or CH2, A is A1, L is L2, L3 or is not present, D is D1 and m is 1.
[0019] Preferred examples of a compound of general formula I are: M 264576 Registration text.docx M 264576 Registration text.docx M 264576 Registration text.docx M 264576 Registration text.docx M 264576 Registration text.docx
[0020] Compound TKR2-14 is a compound of general formula I, where D is Dl, Y is Y2, X is CH2, m is 1, n is 0, and A is Al. Compound TKR2-14 has the sequence specified in SEQ ID NO: 1.
[0021] Compound TKR2-24 is a compound of general formula I, where D is Dl, Y is Y2, XO is, m is 1, n is 0, and A is Al. Compound TKR2-24 has the sequence specified in SEQ ID NO: 2.
[0022] Compound TKR2-80 is a compound of general formula I, where D is Dl, Y is Y1, XO is, m is 1, n is 0, and A is Al. Compound TKR2-80 has the sequence specified in SEQ ID NO: 3.
[0023] Compound TKR2-84 is a compound of general formula I, where D is Dl, Y is Y2, XO is, m is 1, n is 1, L is L5 with p = 2, and A is A6. Compound TKR2-84 has the sequence specified in SEQ ID NO: 4.
[0024] Compound TKR3-08 is a compound of general formula I, where D is Dl, Y is Y2, XO is, m is 1, n is 1, L is L8 with p = 1, and A is Al. Compound TKR3-08 has the sequence specified in SEQ ID NO: 5. M 264576 Registration text.docx
[0025] Compound TKR3-18 is a compound of general formula I, where D is Dl, Y is Y3, m is 1, n is 0, and A is Al. Compound TKR3-18 has the sequence specified in SEQ ID NO: 6.
[0026] Compound TKR3-30 is a compound of general formula I, where D is Dl, Y is Y2, XO is, m is 1, n is 1, L is L2 with p = 1, and A is Al. Compound TKR3-30 has the sequence given in SEQ ID NO: 7.
[0027] Compound TKR3-34 is a compound of general formula I, where D is Dl, Y is Y2, XO is, m is 1, n is 1, L is L2 with p = 7, and A is Al. Compound TKR3-34 has the sequence given in SEQ ID NO: 8.
[0028] Compound TKR3-42 is a compound of general formula I, where D is Dl, Y is Y2, XO is, m is 1, n is 0, and A is A9 with Z = N. Compound TKR3-42 has the sequence specified in SEQ ID NO: 9.
[0029] Compound TKR3-46 is a compound of general formula I, where D is Dl, Y is Y2, XO is, m is 1, n is 1, L is L3 with p = 10, and A is Al. Compound TKR3-46 has the sequence given in SEQ ID NO: 10.
[0030] In one embodiment of the present one, in the compounds of general formula I, if A is A9, F [ 18 F]F' and if A is A10, I [ 123 I]I', [ 124 I]I', [ 125 I]I', [ 131 I]I', preferred [ 123 I]I'.
[0031] According to the invention, a complex is further provided consisting of a compound of general formula I, wherein A is Al to A8, and a radioactive metal ion or A1[ 18 F]F 2+ consists.
[0032] It may be provided that the radioactive metal ion of the complex is selected from the group consisting of [ 61 Cu]Cu 2+ , [ 64 Cu]Cu 2+ , [ 67 Cu]Cu 2+ , [67 Ga]Ga 3+ , [ 68 Ga]Ga 3+ , [ 177 Lu]Lu 3+ , [ 149 [Tb]Tb 3+ , [ 155 [Tb]Tb 3+ , [ 152 [Tb]Tb 3+ , [ 161 [Tb]Tb 3+ , [ 225 Ac]Ac 3+ , [ 226 Ac]Ac 3+ , [ 132 La]La 3+ , [ 133 La]La 3+ , [ 135 La]La 3+ , [ 111 In]In 3+ , [ 86 Y]Y 3+ , M 264576 Registration text.docx[ 90 Y]Y 3+ , [ 212 Bi]Bi 3+ , [ 213 Bi]Bi 3+ , [ 43 Sc]Sc 3+ , [ 44 Sc]Sc 3+ , [ 47 Sc]Sc 3+ , [ 203 Pb]Pb 3+ , [ 212 Pb]Pb 3+ consists.
[0033] It may be provided that the complex consists of a compound of the general formula I, where A is Al, and A1[ 18 F]F 2+ , [ 61 Cu]Cu 2+ , [ 64 Cu]Cu2+ , [ 67 Cu]Cu 2+ , [ 67 Ga]Ga 3+ , [ 68 Ga]Ga 3+ , [ 43 Sc]Sc 3+ or [ 44 Sc]Sc 3+ , [ 47 Sc]Sc 3+ , preferably A1[ 18 F]F 2+ , [ 64 Cu]Cu 2+ or [ 68 Ga]Ga 3+ , especially preferred [ 64 Cu]Cu 2+ or [ 68 Ga]Ga 3+ consists.
[0034] It may be provided that the complex consists of a compound of the general formula I, where A is A2, and A1[ 18 F]F 2+ , [ 61 Cu]Cu 2+ , [ 64 Cu]Cu 2+ , [ 67 Cu]Cu 2+ , [ 67 Ga]Ga 3+ , [ 68 Ga]Ga 3+ , [ 43 Sc]Sc 3+ or [ 44 Sc]Sc 3+ , [ 47 Sc]Sc 3+ , preferably A1[ 18 F]F 2+ , [ 64 Cu]Cu 2+ or [ 68 Ga]Ga 3+, especially preferred [ 64 Cu]Cu 2+ or [ 68 Ga]Ga 3+ consists.
[0035] It may be provided that the complex consists of a compound of the general formula I, where A is A3, and [ 61 Cu]Cu 2+ , [ 64 Cu]Cu 2+ , [ 67 Cu]Cu 2+ , [ 67 Ga]Ga 3+ , [ 68 Ga]Ga 3+ , [ 177 Lu]Lu 3+ , [ 149 [Tb]Tb 3+ , [ 155 [Tb]Tb 3+ , [ 152 [Tb]Tb 3+ , [ 161 [Tb]Tb 3+ , [ 225 Ac]Ac 3+ , [ 226 Ac]Ac 3+ , [ 132 La]La 3+ , [ 133 La]La 3+ , [ 135 La]La 3+ , [ 111 In]In 3+ , [ 86 Y]Y 3+ , [ 90 Y]Y 3+ , [ 212 Bi]Bi 3+ , [ 213 Bi]Bi 3+ , [ 43 Sc]Sc 3+ , [ 44 Sc]Sc 3+ , [ 47 Sc]Sc3+ , [ 203 Pb]Pb 3+ or [ 212 Pb]Pb 3+ preferably [ 133 La]La 3+ , [ 64 Cu]Cu 2+ or [ 68 Ga]Ga 3+ , especially preferred [ 64 Cu]Cu 2+ or [ 68 Ga]Ga 3+ consists.
[0036] It may be provided that the complex consists of a compound of the general formula I, where A is A4, and A1[ 18 F]F 2+ consists.
[0037] It may be provided that the complex consists of a compound of the general formula I, where A is A5, and [ 61 Cu]Cu 2+ , [ 64 Cu]Cu 2+ or [ 67 Cu]Cu 2+ , preferably [ 64 Cu]Cu 2+ consists.
[0038] It may be provided that the complex consists of a compound of the general formula I, where A is A6, and A1[ 18 F]F 2+ , [ 67 Ga]Ga 3+ , [ 68 Ga]Ga 3+or [ 111 In]In 3+ , preferably A1[ 18 F]F 2+ or [ 68 Ga]Ga 3+ , especially preferred [ 68 Ga]Ga 3+ consists. M 264576 Registration text.docx
[0039] It may be provided that the complex consists of a compound of the general formula I, where A is A7, and [ 61 Cu]Cu 2+ , [ 64 Cu]Cu 2+ or [ 67 Cu]Cu 2+ , preferably [ 64 Cu]Cu 2+ consists.
[0040] It may be provided that the complex consists of a compound of the general formula I, where A is A8, and [ 177 Lu]Lu 3+ , [ 149 [Tb]Tb 3+ , [ 155 [Tb]Tb 3+ , [ 152 [Tb]Tb 3+ , [ 161 [Tb]Tb 3+ , [ 225 Ac]Ac 3+ , [ 226 Ac]Ac 3+ , [ 132 La]La 3+ , [ 133 La]La 3+ , [ 135 La]La 3+ , [212 Bi]Bi 3+ , [ 213 Bi]Bi 3+ , [ 203 Pb]Pb 3+ or [ 212 Pb]Pb 3+ , preferably [ 225 Ac]Ac 3+ or [ 133 La]La 3+ , especially preferred [ 133 La]La 3+ consists.
[0041] Particularly preferred is a complex consisting of a compound of the general formula I, where A is Al, and [ 64 Cu]Cu 2+ or [ 68 Ga]Ga 3+ .
[0042] Particularly preferred is a complex of a compound of general formula I, in which Y is Y2, XO or CEE, A is Al, L is L2, L3 or not present, D is Dl and m is 1, and [ 64 Cu]Cu 2+ or [ 68 Ga]Ga 3+ .
[0043] Compounds of general formula I can be combined by coupling a compound of general formula II. M 264576 Registration text.docx (Formula II) to a compound of general formula III H ° ^ L “ A O (Formula III) or a combination of the general formula IV (Formula IV) The coupling is obtained using O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HATU). The coupling is preferably carried out under oscillating mixing.
[0044] The compounds of general formula II are hereinafter also referred to as peptides according to the invention. The peptides according to the invention can be synthesized by automated microwave-assisted solid-phase peptide synthesis (SPPS) using an initiator, Astra, from Biotage. Fmoc-Rink amide resin can be used as the starting material. Using an automated microwave peptide synthesizer and by repeated cycles of Fmoc removal (piperidine / DMF) and coupling (HATU / DIPEA / DMF), the peptides can be built up. Subsequently, the peptides according to the invention can be manually coupled (HATU / DIPEA / DMF) with chelators or other compounds suitable for radiosynthesis. Afterward, they are cleaved from the resin and all protecting groups are removed by treatment with TFA / H2O / TIPS. Following the removal of TFA, the peptides are precipitated with ice-cold diethyl ether.The linear peptide was dissolved in a mixture of acetonitrile and water and diluted with NH4HCO3 (100 mM). TCEP was added to the solution. The reaction was initiated by the addition of TATA. After completion of the reaction, the pH was adjusted to 2.0 with TFA / water. The solution was then lyophilized and purified by RP-HPLC.
[0045] According to the invention, the compounds of general formula I can be used as a pharmaceutical, preferably as a pharmaceutical for the diagnosis and treatment of diseases involving the cell surface protein Nectin-4. The pharmaceutical is preferably a pharmaceutical for the diagnosis and treatment of bladder cancer and breast cancer.
[0046] According to the invention, the use of a compound of general formula I according to the invention is provided for in the production of radiopharmaceuticals. Details of the production of the radiopharmaceuticals are explained in more detail in the Examples section.
[0047] Unless otherwise specified, the term "alkyl" refers in particular to a saturated aliphatic hydrocarbon group with a branched or unbranched carbon chain having 1 to 12 carbon atoms, preferably 1 to 8 carbon atoms, and particularly preferably 1 to 6 carbon atoms. Examples of alkyl groups include, but are not limited to, methyl, ethyl, propyl, isopropyl, isobutyl, sec-butyl, tert-butyl, pentyl, n-hexyl, octyl, dodecyl, and the like. The alkyl group may optionally be substituted with one or more substituents. M 264576 Registration text.docx
[0048] The term “acyl” refers to a group of the formula -C(O)-R, where R is alkyl as defined herein.
[0049] The invention is explained in more detail below with reference to exemplary embodiments, which are not intended to limit the invention, and with reference to the drawings. These show Fig. 1 Cell binding and internalization of the 64 Cu-labeled compounds TKR2-08 (reference compound), TKR2-14, TKR2-24, TKR2-80, TKR3-08, TKR3-18, TKR3-30, TKR3-34, TKR3-40 and TKR3-46 on Nectin-4-positive (HT-1376) and Nectin-4-negative (5637) cells; Fig. 2 Cell binding and internalization of the 68 Ga-labeled compounds TKR2-08, TKR2-24 and TKR4-48 (corresponding to prior art compound N188) on Nectin-4-positive (HT-1376) and Nectin-4-negative (5637) cells; Fig. 3 Saturation binding curves of the 64 Cu-labeled compounds TKR2-08 (A), TKR2-24 (B), TKR3-08 (C), TKR3-34 (D) and TKR3-46 (E); Fig. 4 Saturation binding curves of the 68 Ga-labeled compounds TKR2-08 (A), TKR4-48 (=N188) (B) and TKR2-24 (C); Fig. 5 Time-dependent SUV curves for the uptake of radioligands in HT-1376 tumors (A) and the time courses of the tumor-to-muscle (B), tumor-to-heart (C), tumor-to-kidney (D) and tumor-to-liver (E) ratios for the 64 Cu-labeled compounds TKR2-08, TKR2-14, TKR2-24, TKR3-08, TKR3-34 and TKR3-46 in tumor-bearing mice; Fig. 6 Time-dependent SUV curves for the uptake of radioligands in HT-1376 tumors (A) and the time courses of the tumor-to-muscle (B), tumor-to-heart (C), tumor-to-kidney (D) and tumor-to-liver (E) ratios for the 68 Ga-labeled compounds TKR2-08, TKR4-48 (=N188) and TKR2-24 in tumor-bearing mice; Fig. 7 analytical radio-HPLC chromatograms according to 64 Cu- or 68 Ga-Marking: [ 64Cu]Cu-TKR2-08 with evidence that the resulting impurity during radiolabeling is the corresponding peptide with methionine sulfoxide-M 264576 application text.docx. The rest is (A), [ 64 Cu]Cu-TKR2-24 (B), [ 68 Ga]Ga-TKR2-08 where magnification also shows the formation of the corresponding sulfoxide (C), [ 68 Ga]Ga- TKR2-52 where magnification also shows the formation of the corresponding sulfoxide (D) and Fig. 8 time-dependent degradation of the 64 Cu-labeled ligands TKR2-08, TKR2-24, TKR2-44 and TKR2-50 by incubation in 0.001% H2O2 solution. Example 1 Synthesis of TKR2-24
[0050] The compound TKR2-24 was synthesized by automated microwave-assisted solid-phase peptide synthesis (SPPS) using Biotage's Astra initiator. Fmoc rink amide resin (139 mg, 0.1 mmol, 0.72 mmol / g) was used as the starting material and swelled in DMF (2 ml / 0.1 mmol) under oscillating mixing and microwave heating (70 °C) for 30 min. Fmoc removal was achieved using two cycles of 20% piperidine in DMF containing 0.1 M HOBt (2 mL, 2 mL / 0.1 mmol), each for 10 min. The resin was washed twice with DMF and HATU (152 mg, 0.4 mmol, 4 eq., 0.5 min DMF), followed by the addition of DIPEA (68 pL, 0.8 mmol, 8 eq., 2 M in 7V-methyl-2-pyrrolidinone (NMP)) and Fmoc-L-Cys(Trt)-OH (234 mg, 0.4 mmol, 4 eq., 0.2 M in DMF). Coupling was performed under oscillating mixing at room temperature for 60 min. The resin was then washed twice with DMF, followed by another cycle of Fmoc removal as described above. HATU (152 mg, 0.4 mmol, 4 eq., 0.5 M in DMF), DIPEA (68 pl, 0.8 mmol, 8 eq., 2 M in 7V-Methyl-2-pyrrolidinone (NMP)) and Fmoc-L-Trp(Boc)-OH (211 mg, 0.4 mmol, 4 eq., 0.2 M in DMF) were added. Coupling was performed under oscillating mixing and microwave heating (75 °C) for 5 min. Further peptide assembly was carried out by alternating cycles of Fmoc removal and amino acid coupling with Fmoc-L-Cys(Trt)-OH and Fmoc-L-HArg(Pbf)-OH, which were coupled at room temperature for 60 min, and Fmoc-L-Hyp(tBu)-OH, Fmoc-L-Pro-OH, Fmoc-D-Asp(tBu)-OH, Fmoc-L-Ser(tBu)-OH, Fmoc-L-Trp(Boc)-OH, Fmoc-L-Thr(tBu)-OH, Fmoc-L-Mox-OH, Fmoc-L-Asp(tBu)-OH, and Fmoc-lNal-OH, which were coupled under microwave heating (75 °C) for 5 min. After the coupling of the... M 264576 Registration text.docx After the last Fmoc-L-Cys(Trt)-OH, another cycle of Fmoc removal was carried out and the resin was washed twice with DMF. To the swollen resin (0.025 mmol) in DMF (2 ml / 0.1 mmol) ()-NO-DAGA(tBu)3 (27 mg, 0.05 mmol, 2 eq., 0.2 M in DMF), DIPEA (0.1 mmol, 17 pl, 4 eq.) and HATU (19 mg, 0.05 mmol, 1 eq., 0.5 M in DMF) were added. The mixture was shaken for 12 h. The resin was washed with DMF, CH2Cl2, CH3OH, and diethyl ether (each twice). The resin was dried in an oven at 50 °C for 30 min. To the dry resin (0.025 mmol) TIPS (125 µl) and H₂O (125 µl) were added, followed by TFA (2.5 mL). The resin was shaken for 4 h at 40 °C. The eluate and an additional volume of TFA (2 mL) for washing were collected and dried using a nitrogen stream. Ice-cold diethyl ether (35 mL) was added, and the peptide was precipitated at -20 °C for 2 h. This was followed by centrifugation (7.142 g) for 4 min at 4 °C. The supernatant was removed, and ice-cold diethyl ether (35 mL) was added again, followed by centrifugation (7.142 g) for 4 min at 4 °C. The supernatant was again removed, and the peptide pellet was dried in an oven at 50 °C for 30 min. The linear peptide was dissolved in a 1:1 (vol / vol) mixture of acetonitrile / water (2 ml) and diluted with NH4HCO3 (100 mM, 23 ml) to a final concentration of 1 mM peptide. TCEP (0.025 mmol, 6 mg, 1 eq.) was added to this solution.The cyclization was initiated by adding TATA (8 mg, 0.0325 mmol, 1.3 eq) and the mixture was shaken for 1 h at 30 °C. The pH was then adjusted to 2.0 with 10% TFA / water. This solution was then lyophilized and the crude peptide product was purified by RP-HPLC. Synthesis of TKR2-08
[0051] The synthesis of TKR2-08 was carried out according to the procedure for TKR2-24, starting from Fmoc-Rink-amide resin (139 mg, 0.1 mmol, 0.71 mmol / g). In contrast to TKR2-24, Fmoc-L-Met-OH (149 mg, 0.4 mmol, 4 eq., M 264576 application text.docx, 0.2 M in DMF) was used as the amino acid building block for position 4. Furthermore, for the N-terminal acylation, (A)-NODAGA(tBu)3 (27 mg, 0.05 mmol, 2 eq., 0.2 M in DMF), DIPEA (0.1 mmol, 17 µl, 4 eq.) and HATU (19 mg, 0.05 mmol, 2 eq., 0.5 M in DMF) were added to the pre-swollen resin (0.025 mmol) and the reaction mixture was shaken for 12 h. Compound TKR2-08 is a compound corresponding to a compound of the general formula I, where D is Dl, Y is Y2, except that in this case X is S, m is 1, n is 0 and A is Al. Example 3 Synthesis of TKR2-14
[0052] The synthesis of TKR2-14 was carried out according to the procedure for TKR2-24, starting from Fmoc-Rink-amide resin (139 mg, 0.1 mmol, 0.72 mmol / g). In contrast to TKR2-24, Fmoc-L-Nle-OH (141 mg, 0.4 mmol, 4 eq., 0.2 M in DMF) was used as the amino acid building block for position 4. Furthermore, for the N-terminal acylation, (A)-NODAGA(tBu)s (27 mg, 0.05 mmol, 2 eq., 0.2 M in DMF), DIPEA (0.1 mmol, 17 g, 4 eq.) and HATU (19 mg, 0.05 mmol, 2 eq., 0.5 M in DMF) were added to the pre-swollen resin (0.025 mmol) and the reaction mixture was shaken for 12 h. Example 4 Synthesis of TKR2-44
[0053] The synthesis of TKR2-44 was carried out according to the procedure for TKR2-24, starting from Fmoc-Rink amide resin (139 mg, 0.1 mmol, 0.72 mmol / g). In contrast to TKR2-24, Fmoc-L-selenomethionine-OH (167 mg, 0.4 mmol, 4 eq., 0.2 M in DMF) was used as the amino acid building block for position 4. Furthermore, for the N-terminal acylation, (A)-NODAGA(tBu)s (27 mg, 0.05 mmol, 2 eq., 0.2 M in DMF), DIPEA (0.1 mmol, 17 g, 4 eq.) and HATU (19 mg, 0.05 mmol, 2 eq., 0.5 M in DMF) were added to the pre-swollen resin (0.025 mmol) and the reaction mixture was shaken for 12 h. M 264576 Registration text.docx Example 5 Synthesis of TKR2-80
[0054] The synthesis of TKR2-80 was carried out according to the procedure for TKR2-24, starting from Fmoc-Rink amide resin (139 mg, 0.1 mmol, 0.72 mmol / g). In contrast to TKR2-24, Fmoc-L-Ser(Et)-OH (142 mg, 0.4 mmol, 4 eq., 0.2 M in DMF) was used as the amino acid building block for position 4. Furthermore, for the N-terminal acylation, ( / ?)-NODAGA(tBu)3 (27 mg, 0.05 mmol, 2 eq., 0.2 M in DMF), DIPEA (0.1 mmol, 17 pl, 4 eq.) and HATU (19 mg, 0.05 mmol, 2 eq., 0.5 M in DMF) were added to the pre-swollen resin (0.025 mmol) and the reaction mixture was shaken for 12 h. Example 6 Synthesis of TKR2-84
[0055] The synthesis of TKR2-84 was carried out according to the procedure for TKR2-24, starting from Fmoc-Rink amide resin (139 mg, 0.1 mmol, 0.72 mmol / g). In contrast to TKR2-24, 3-(2-(2-(4-(((2-Bis(2-(tert-butoxy)-2-oxo-ethyl)amino)cyclohexyl)(2-(tert-butoxy)-2-oxoethyl)amino)methyl)-1H-1,2,3-triazol-1-yl)ethoxy)ethoxy)ethoxy)propanoic acid was used for the N-terminal acylation. This building block was prepared by using di-tert-butyl-2,2'-((2-((2-(tert-butoxy)-2-oxo-ethyl)(prop-2-yn-1-yl)amino)cyclohexyl)azandiyl)diacetate. 16(22 mg, 0.045 mmol, 1 eq.) was dissolved together with N3-Peg3-OH (11 mg, 0.045 mmol, 1 eq.) in DMF (2 mL). CuSO4×5H2O (5 mg, 0.02 mmol, 0.5 eq.) and THPTA (12 mg, 0.02 mmol, 0.5 eq.) were dissolved in water (100 pL) and added to the solution. Sodium ascorbate (13 mg, 0.07 mmol, 1.5 eq.) was dissolved in water (100 pL) and added to the solution. The reaction was carried out for 3 hours at room temperature. The solvent was removed under vacuum, and the residue was dissolved in water (3 mL) and extracted with ethyl acetate (3 x 3 mL). The combined organic phase was dried over MgSO4, and the solvent was removed under vacuum. The residue was used in the next step without further purification. For the N-terminal acylation, 3-(2-(2-(4-(((2-Bis(2-(tert-butoxy)-2-oxoethyl)amino)cyclohexyl)(2-(tert-butoxy)- 2-oxoethyl)amino)methyl)-1H-1,2,3-triazol-1-yl)ethoxy)ethoxy)ethoxy)propanoic acid was used. M 264576 Registration text.docx (14 mg, 0.019 mmol, 1.5 eq., 0.2 M in DMF), DIPEA (0.019 mmol, 7 pl, 4 eq.) and HATU (7 mg, 0.019 mmol, 1.5 eq., 0.5 M in DMF) were added to the swollen resin (0.0125 mmol) and the mixture was shaken for 4 h. Example 7 Synthesis of TKR3-08
[0056] The synthesis of TKR3-08 was carried out according to the procedure for TKR2-24, starting from Fmoc-Rink amide resin (35 mg, 0.025 mmol, 0.72 mmol / g). In contrast to TKR2-24, Fmoc-L-O2Oc-OH (39 mg, 0.4 mmol, 4 eq., 0.2 M in DMF) was used as the amino acid building block for N-terminal acylation. 2-((((9-Fluoren-9-yl)methoxy)carbonyl)amino)-3-(1-(4-(((S)-1-amino-1-oxo-6-(4-(-tolyl)butanamido)hexan-2-yl)carbamoyl)phenyl)-1H-1,2,3-triazol-4-yl)propanoic acid was synthesized by dissolving Fmoc-Pra-OH (21 mg, 0.064 mmol, 2 eq.) and (S)-N-(1-Amino-1-oxo-6-(4-(p-tolyl)butanamido)hexan-2-yl)-4-azidobenzamide 17(14 mg, 0.032 mmol, 1 eq.) in DMF (2 mL). CuSO₄ × 5H₂O (4 mg, 0.016 mmol, 0.5 eq.) and THPTA (8 mg, 0.016 mmol, 0.5 eq.) were dissolved in water (100 lp) and added to the solution. Sodium ascorbate (19 mg, 0.095 mmol, 3 eq.) was dissolved in water (100 lp) and added to the solution. The reaction was carried out for 3 hours at room temperature. The solvent was removed under vacuum, and the residue was purified by RP-HPLC. For further N-terminal acylation, 2-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-3-(1-(4-(((S)-1-amino-1-oxo-6-(4-(p-tolyl)butanamido)hexan-2-yl)carbamoyl)phenyl)-1H-1,2,3-triazol-4-yl)propanoic acid (9 mg, 0.011 mmol, 1.1 eq., 0.2 M in DMF), DIPEA (0.022 mmol, 4 pl, 2.2 eq.) and PyBOP (6 mg, 0.011 mmol, 1.1 eq., 0.5 M in DMF) were added to the swollen resin (0.01 mmol) and the mixture was shaken for 12 h. Example 8 Synthesis of TKR3-18 M 264576 Registration text.docx
[0057] The synthesis of TKR3-18 was carried out according to the procedure for TKR2-24, starting from Fmoc-Rink amide resin (139 mg, 0.1 mmol, 0.72 mmol / g). In contrast to TKR2-24, Fmoc-L-Cys(Et)-OH (149 mg, 0.4 mmol, 4 eq., 0.2 M in DMF) was used as the amino acid building block for position 4. Furthermore, for the N-terminal acylation, (A)-NODAGA(tBu)a (27 mg, 0.05 mmol, 2 eq., 0.2 M in DMF), DIPEA (0.1 mmol, 17 pl, 4 eq.) and HATU (19 mg, 0.05 mmol, 2 eq., 0.5 M in DMF) were added to the pre-swollen resin (0.025 mmol) and the reaction mixture was shaken for 12 h. Example 9 Synthesis of TKR3-30
[0058] The synthesis of TKR3-30 was carried out according to the procedure for TKR2-24, starting from Fmoc-Rink amide resin (35 mg, 0.025 mmol, 0.72 mmol / g). In contrast to TKR2-24, Fmoc-L-O2Oc-OH (39 mg, 0.1 mmol, 4 eq., 0.2 M in DMF) was used as the amino acid building block for N-terminal acylation. Furthermore, for further N-terminal acylation, (A)-NODAGA(tBu)s (27 mg, 0.05 mmol, 2 eq., 0.2 M in DMF), DIPEA (0.1 mmol, 17 pl, 4 eq.) and HATU (19 mg, 0.05 mmol, 2 eq., 0.5 M in DMF) were added to the pre-swollen resin (0.025 mmol) and the reaction mixture was shaken for 12 h. Example 10 Synthesis of TKR3-34
[0059] The synthesis of TKR3-34 was carried out according to the procedure for TKR2-24, starting from Fmoc-Rink amide resin (35 mg, 0.025 mmol, 0.72 mmol / g). In contrast to TKR2-24, Fmoc-Pegs-OH (65 mg, 0.4 mmol, 4 eq., 0.2 M in DMF) was used as the amino acid building block for N-terminal acylation. Furthermore, for further N-terminal acylation, (A)-NODAGA(tBu)s (27 mg, 0.05 mmol, 2 eq., 0.2 M in DMF), DIPEA (0.1 mmol, 17 pl, 4 eq.) and HATU (19 mg, 0.05 mmol, 2 eq., 0.5 M in DMF) were added to the pre-swollen resin (0.025 mmol) and the reaction mixture was shaken for 12 h. M 264576 Registration text.docx Example 11 Synthesis of TKR3-40
[0060] The synthesis of TKR3-40 was carried out according to the procedure for TKR2-24, starting from Fmoc-Rink-amide resin (175 mg, 0.1 mmol, 0.72 mmol / g). In contrast to TKR2-24, Fmoc-L-2Nal-OH (142 mg, 0.4 mmol, 4 eq., 0.2 M in DMF) was used as the amino acid building block for position 2. Furthermore, for the N-terminal acylation, ( / ?)-NODAGA(tBu)3 (27 mg, 0.05 mmol, 2 eq., 0.2 M in DMF), DIPEA (0.1 mmol, 17 pl, 4 eq.) and HATU (19 mg, 0.05 mmol, 1.5 eq., 0.5 M in DMF) were added to the pre-swollen resin (0.025 mmol) and the reaction mixture was shaken for 12 h. Example 12 Synthesis of TKR3-42
[0061] The synthesis of TKR3-42 was carried out according to the procedure for TKR2-24, starting from Fmoc-Rink amide resin (175 mg, 0.1 mmol, 0.72 mmol / g). In contrast to TKR2-24, for the N-terminal acylation, 6-fluoronicotinic acid (5.3 mg, 0.0375 mmol, 1.5 eq., 0.2 M in DMF), DIPEA (0.1 mmol, 13 pl, 3 eq.), and HATU (14 mg, 0.0375 mmol, 1.5 eq., 0.5 M in DMF) were added to the pre-swollen resin (0.025 mmol), and the reaction mixture was shaken for 2 h. Example 13 Synthesis of TKR3-46
[0062] The synthesis of TKR3-46 was carried out according to the procedure for TKR2-24, starting from Fmoc-Rink amide resin (175 mg, 0.1 mmol, 0.72 mmol / g). In contrast to TKR2-24, Fmoc-Sar-OH (125 mg, 0.4 mmol, 4 eq., 0.2 M in DMF) was used ten times and Fmoc-3-aminopropanoic acid (15.6 mg, 0.05 mmol, 2 eq., 0.2 M in DMF) once for the N-terminal acylation. For further N-terminal acylation, ( / ?)-NODAGA(tBu)3 (27 mg, 0.05 mmol, 2 eq., 0.2 M in DMF), DIPEA (0.1 mmol, 17 pl, 4 eq.) and HATU (19 mg, 0.05 mmol, 2 eq., 0.5 M in DMF) were added to the pre-swollen resin (0.025 mmol) and the reaction mixture was shaken for 12 h. M 264576 Application text.docx The mass spectrometric data, purity and yield of the compounds of the invention of Examples 1 to 13 are set out in the following Table 2. Table 2 a High-resolution mass spectrometry was performed. bThe chemical purity was determined using analytical RP-HPLC and is specified for 230 nm. c m / z calculated for [M+Cu 2+ ] 2+ d m / z found for [M+Cu 2+ ] 2+ Example 14 Fluorescence anisotropy-based competition assay for determining binding affinities ( d -values) of the non-radioactive peptides compared to recombinant human Nectin-4
[0063] All experiments were performed at 37°C for 1200 s (37 s interval) using a Cytation 5 multimode microplate reader (BioTek Instruments, Gen 5 software) and black microtiter plates (BRAND plates with F-bottom (96-well)). Fluorescence intensities were measured at an excitation wavelength of 540 nm and an emission wavelength of 620 nm. Fluorescence anisotropy values (FA values in r) were calculated by the Gen 5 software based on the measured parallel M 264576 Registration text.docx(I∥) and perpendicular (I⊥) fluorescence intensities calculated according to equation I and a G-factor of 0.87. Further data analysis was performed using GraphPad Prism (version 10.4.1, GraphPad Software, San Diego, CA, USA). The test solutions (100 µL) contained an aqueous solution (99 µL) and DMSO (1% v / v, 1 µL). For the competitive binding assay, constant concentrations of the fluorescent ligand TKR2-09 (1 nM, compound TKR2-09 is a compound of general formula I, where D is Dl, Y is Y2, XS is, m is 1, n is 0, and A is 6-TAMRA) and human Nectin-4 (20 nM) were established. The displacement of TKR2-09 from Nectin-4 was measured at 10 different concentrations of the unlabeled peptide (e.g., 0.24–500 nM, prepared by serial 1:1 dilution). Stock solutions of TKR2-09 (2.5 nM) and Nectin-4 (50 nM) were prepared in HEPES buffer (20 mM, 50 mM NaCl, 0.01% Tween20, pH 7.4) and stock solutions of the peptides under investigation were prepared in 5% DMSO / HEPES buffer.The stock solution of the peptide (20 pL) was pipetted to Nectin-4 (40 pL) and TKR2-09 (40 pL), and the measurement was then started. The FA values were averaged over 1200 s, and the representation of the FA values as a function of peptide concentration was analyzed by nonlinear regression based on the model “[inhibitor] vs. response - Variable slope (four parameters)” (implemented in GraphPad Prism). The obtained IC50 values were calculated according to the mathematical equation by Nikolovska-Coleska et al. 18 converted (Ä7i of TKR2-09 is 0.94 nM). Table 3 below shows the Kd values of the compounds according to the invention of examples 1 to 13 and additionally of the compounds TKR2-03, TKR2-08 and TKR4-48 (corresponding to the prior art compound N188). M 264576 Registration text.docx Table 3 The data shown are means with estimated confidence intervals (68%) from three separate experiments (performed in duplicate). Compound TKR2-03 is a compound corresponding to a compound of general formula I, where D is Dl, Y is Y2, except that in this case X is S, m is 1, n is 0, and A is acetyl. Compound TKR2-08-O is a compound corresponding to a compound of general formula I, where D is Dl, Y is Y2, except that in this case X is SO, m is 1, n is 0, and A is Al. TKR4-48 corresponds to prior art compound N188. Compound TKR2-50 is a compound corresponding to a compound of general formula I, where D is Dl, Y is Y2, except that in this case X is S, m is 0, n is 0, and A is Al. It can be seen that the replacement of methionine (contained in TKR2-08, TKR2-50, TKR2-52) with methoxinine (TKR2-24) or norleucine (TKR2-14) is tolerated with respect to binding affinity towards Nectin-4, as at least comparably good binding affinities are achieved. However, the methionine sulfoxide residue (TKR2-08-O) is significantly less well tolerated, which means that the susceptibility of methionine to oxidation subsequently affects its binding behavior towards Nectin-4. M 264576 Registration text.docx Cell binding and internalization 64 Cu and 68 Ga-labeled compounds
[0064] HT-1376 cells were cultured in DMEM and HT-5637 cells in RPMI media enriched with 10% FBS and 1% penicillin / streptomycin at 5% CO2 and 37°C. The cells were seeded into 48-well plates four days prior to the experiment (HT-1376: 50,000 cells / well, HT-5637: 30,000 cells / well). DMEM medium was used for both cell types for the binding assay. All cells were washed once with fresh medium prior to the experiment. To determine total binding, the radioligand was diluted to 10 nM in DMEM medium and added to the cells. Non-specific binding of the radioligand was determined in the presence of compound TKR2-03 (1 pM in well). The plates were incubated at 37 °C for 1 h (shaken at 300 rpm). After incubation, the cells were treated twice with cold PBS. + The samples were washed for approximately 5 minutes. To determine the internalized fraction of bound radioligand, a wash step with cold PBS was performed. +The cells were replaced by treatment with cold glycine buffer (50 mM, pH 2.3) for 5 min. Subsequently, the cells were lysed with 0.1% SDS in 0.1 M NaOH. The lysates were measured using a y-counter. The results were normalized against the protein content of the lysates, which was determined using a NanoDrop spectrophotometer. To obtain the data for specific binding, the non-specific binding data were subtracted from the total binding data. Figure 1 shows cell binding and internalization of the 64 Cu-labeled compounds TKR2-08, TKR2-14, TKR2-24, TKR2-80, TKR3-08, TKR3-18, TKR3-30, TKR3-34, TKR3-40, and TKR3-46 are shown on Nectin-4-positive (HT-1376) and Nectin-4-negative (5637) cells. Figure 2 shows cell binding and internalization of the compounds. 66 Ga-labeled compounds TKR2-08, TKR2-24 and TKR4-48 (corresponding to state-of-the-art compound N188) are shown in Nectin-4 positive (HT-1376) and Nectin-4 negative (5637) cells.
[0065] For the saturation binding assay, total and non-specific binding were determined as described above using 10 different radioligand concentrations (0.156–80 nM or 0.321–160 nM) prepared by serial 1:1 dilution. Plots of “total binding” = f(radioligand) were analyzed by non-linear regressions using the “one site-total, accounting for ligand depletion” model as implemented in GraphPad Prism, and plots of “non-specific binding” = f(radioligand) were analyzed by linear regressions.
[0066] Figure 3 shows the saturation binding curves for the 64Cu-labeled ligands TKR2-08 (A), TKR2-24 (B), TKR3-08 (C), TKR3-34 (D), and TKR3-46 (E) are shown with total binding in black, non-specific binding (in the presence of excess non-radioactive ligand) in gray, and specific binding as a circle, triangle pointing upwards, or triangle pointing downwards. The data points represent mean values (±SD) from an experiment performed in multiple determinations (5). Table 4 below shows the obtained values for Kd and Bmax, including the coefficient of determination (R). 2 ) summarized. It can be seen that the methionine substitution by metho-xinine also has an effect on the binding of the 64 Cu-labeled ligands do not cause any disadvantages on cells. Table 4
[0067] Figure 4 shows the saturation binding curves for the 68Ga-labeled ligands TKR2-08 (A), TKR2-52 (B), and TKR2-24 (C) are shown with total binding in black, non-specific binding (in the presence of excess non-radioactive ligand) in gray, and specific binding as a circle, triangle pointing upwards, or triangle pointing downwards, respectively. The data points represent mean values (±SD) from an experiment performed in multiple determinations (5). Table 5 below shows the obtained values for KdM 264576 and Bmax, including the coefficient of determination (R). 2 ) summarized. It can be seen that the methionine substitution by methoxinine also has an effect on the binding of the 68 Ga-labeled ligands do not cause any disadvantages on cells. Table 5 The TKR4-48 connection corresponds to the N188 connection of the state of the art. Example 17 Radiolabeling with Cu 2+
[0068] [ 64 Cu]CuCl2 was synthesized at the Helmholtz-Zentrum Dresden-Rossendorf at the 30 MeV TR-Flex cyclotron (Advanced Cyclotron Systems, Inc., ACSI, Canada) using 64 Ni(p,n) 64 Cu nuclear reaction was produced. For a typical radioactive labeling procedure, the [ 64 Cu[CuCl₂] solution was diluted with ammonium acetate buffer (0.1 M, pH 5.6) to obtain a solution with an activity concentration of 1 MBq / ml. A portion (98 pl) of this mixture was then treated with the peptide stock solution (2 pl, 2 mM in DMSO), and the resulting mixture was incubated for 25 min at 60 °C. Quality control of the radiolabeled peptide chelator conjugates was performed by radio-HPLC analysis. Labeling yields were typically > 99%. The radiolabeled peptides were used without purification. Example 18 Radiographic marking with [ 68 Ga]Ga 3+
[0069] [68 Ga]GaCl3 was dissolved with 0.1 M HCl from a 68 Ge / 68 Ga generator eluted. For a typical radioactive labeling procedure, the [ 68 Ga]GaCl3 solution was diluted with sodium acetate buffer (1 M, pH 4.5). A portion of this mixture was then M 264576 Registration text.docx of the peptide stock solution (2 mM in DMSO) was added and the mixture was incubated for 10 min at 90 °C. Quality control of the radiolabeled peptide-chelator conjugates was performed by radio-HPLC. Labeling yields were typically > 99%. The radiolabeled peptides were used without further purification. Example 19 Oxidation assay
[0070] Stability under oxidative conditions was investigated by treating the 64Cu-labeled peptides with hydrogen peroxide. For this purpose, a 0.03% solution of H₂O₂ (2 µL) was added to the radiolabeled peptides (2 nmol, 48 pL) and incubated at room temperature. The peptide conjugates were analyzed by radio-HPLC after 3, 5, and 7 hours. The half-life was determined by calculating the percentage of intact compound, and the resulting time-dependent radioligand degradation curves were analyzed using one-phase decay (implemented in GraphPad Prism).
[0071] Figure 8 shows the curves obtained for the time-dependent degradation. 64 Cu-marked variants of the compounds according to the invention of Examples 2, 3 and 4 and of compound TKR2-08 are presented. Table 6 below lists the determined half-lives of the 64Cu-marked variants of the compounds according to the invention of examples 2, 3 and 4 as well as of compound TKR2-08 are presented. M 264576 Registration text.docx Table 6 Compound half-life (h) TKR2-08 3.64 TKR2-24 6.87 TKR2-44 0.38 TKR2-50 3.46 It becomes apparent that replacing methionine (TKR2-08, TKR2-50) with methoxinine (TKR2-24) leads to an improvement in oxidative stability. In contrast, replacing it with selenomethionine (TKR2-44) results in increased susceptibility to oxidation. Example 20 PET quantification of 64 Cu and 68 Ga-marked compounds
[0072] After the tumor volume reached 200 mm³ 3Once the target level had been reached, PET experiments were performed with the radioligands. The ligands were radiolabeled as described above at a molar activity of 25 MBq / nmol. The labeling solutions were diluted in 0.9% NaCl, and approximately 9 MBq (approximately 0.46 nmol) were injected intravenously per mouse. To block Nectin-4 binding, 75 nmol of blocking agent (TKR2-03) was injected simultaneously. A 2-hour PET scan was acquired starting from the time of injection. Additionally, a CT scan was performed. For PET image reconstruction, three-dimensional list-mode data were binned using the 400–600 keV energy window and sorted into 36 timeframes (15 x 0 s, 5 x 30 s, 5 x 60 s, 4 x 300 s, 3 x 600 s, 4 x 900 s). The timeframes were reconstructed using the Tera-Tomo three-dimensional (3D) algorithm with a v-xel size of 0.4 mm, applying corrections for random events, dispersion, attenuation, and radionuclide half-life.
[0073] Figure 5 shows time-dependent SUV curves for the uptake of radioligands in HT-1376 tumors (A) and the time courses of tumor-to-blood (B), tumor-to- M 264576 Registration text.docx Muscle (C), tumor-to-liver (D) and tumor-to-kidney (E) ratios for the 64Cu-labeled compounds TKR2-08, TKR2-14, TKR2-24, TKR3-08, TKR3-34, and TKR3-46 were measured in tumor-bearing mice. Table 7 below summarizes the obtained values. The significance compared to [ 64 Cu]Cu-TKR2-08 was identified and marked(*). Table 7
[0074] Figure 6 shows time-dependent SUV curves for the uptake of radioligands in HT-1376 tumors (A) and the time courses of the tumor-to-blood (B), tumor-to-muscle (C), tumor-to-liver (D) and tumor-to-kidney (E) ratios for the 68 Ga-labeled compounds TKR2-08, TKR4-48 (=N188) and TKR2-24 were measured in tumor-bearing mice. The results are summarized in Table 8 below. M 264576 Registration text.docx Table 8 All animal experiments were conducted in accordance with the guidelines of the German Animal Welfare Ordinance and were approved by the local ethics committee. Xenotransplant tumor models of HT-1376 and -5637 cells were generated in NMRI-enhanced nude mice by subcutaneous cell injection in PBS enriched with 50% (v / v) Matrigel. M 264576 Registration text.docx Abbreviations Boc tert-Butyloxycarbonyl DIPEA Diisopropylethylamine DMF Dimethylformamide DMSO Dimethyl sulfoxide Ethyl Fmoc 9-Fluorenylmethoxycarbonyl HATU [O-(7-Azabenzotriazol- 1 -yl)-N, N, N', N'-tetramethyluronium hexafluorophosphate] HCl hydrochloric acid HEPES N-2-Hydroxyethylpiperazine-N-2-ethanesulfonic acid HOBt 1-Hydroxybenzotriazol HPLC High-Performance Liquid Chromatography Me Methyl PET Positron Emission Tomography PyBOP (Benzotriazol-l-yl-oxytripyrrolidinophosphonium hexafluorophosphate) RP-HPLC Reversed-phase high-performance liquid chromatography SPECT Single-photon emission computed tomography SPPS solid-phase peptide synthesis SUVmean Standardised Intake Value TATA 2,4,6-triamino-l,3,5-triamine TCEP (Tris(2-carboxyethyl)phosphine) TFA Trifluoroacetic acid THPTA Tris(3-hydroxypropyltriazolylmethyl)amine M 264576 Registration text.docx Literature 1. Maas, M.; Stuhler, V.; Walz, S.; Stenzl, A. and Bedke, J. Enfortumab vedotin - next game-changer in urothelial cancer. Expert opinion. Organic / . Ther. 2021, 21, 801-809. 2. Hoffman-Censits, JH; Lombardo, K.A.; Parimi, V.; Kamanda, S.; Choi, W.; Hahn, N. M.; McConkey, D. J.; McGuire, B. M.; Bivalacqua, T. J.; Kates, M. and Matoso, A. Expression of Nectin-4 in Bladder Urothelial Carcinoma, in Morphologie Variants, and Nonurothelial Histotypes. Appl. Immunohistochem. Mol. Morphol. 2021, 29, 619-625. 3. Liu, Y.; Han, X.; Li, L.; Zhang, Y.; Huang, X.; Li, G; Xu, C.; Yin, M.; Zhou, P.; Shi, F.; Liu, X.; Zhang, Y. and Wang, G. Role of Nectin-4 protein in cancer (Review). Int. J. Oncol. 2021, 59. 4. Klümper, N.; Eckstein, M.; Hölzel, M.; Herrmann, K.; Hadaschik, B. and Grünwald, V. Re: First-in-Human Study of the Radioligand (68)Ga-N188 Targeting Nectin-4 for PET / CT Imaging of Advanced Urothelial Carcinoma: Navigating Metastatic Urothelial Cancer with Nectin-4 PET / CT. Eur. Ural. 2023, 84, 514- 515. 5. Rigby, M.; Bennett, G.; Chen, L.; Mudd, G. E.; Harrison, H.; Beswick, P. J.; Van Rietschoten, K.; Watcham, S. M.; Scott, H. S.; Brown, A. N.; Park, P. U.; Campbell, C.; Haines, E.; Lahdenranta, J.; Skynner, M. J.; Jeffrey, P.; Keen, N. and Lee, K. BT8009; A Nectin-4 Targeting Bicycle Toxin Conjugate forTreatment of Solid Tumors. Mo / . Cancer Ther. 2022, 21, 1747-1756. 6. Mudd, G. E.; Scott, H.; Chen, L.; van Rietschoten, K.; Ivanova-Berndt, G.; Dzionek, K.; Brown, A.; Watcham, S.; White, L.; Park, P. U.; Jeffrey, P.; Rigby, M. and Beswick, P. Discovery of BT8009: A Nectin-4 Targeting Bicycle Toxin Conjugate for the Treatment of Cancer. J. Med. Chem. 2022, 65, 14337-14347. 7. Campbell, D. O.; Noda, A.; Verlinsky, A.; Snyder, J.; Fujita, Y.; Murakami, Y.; Fushiki, H.; Miyoshi, S.; Lacayo, S.; Cabral, E.; Yang, P.; Stover, D. R. and Joseph, I. B. Preclinical Evaluation of an Anti -Nectin-4 ImmunoPET Reagent in Tumor-Bearing Mice and Biodistribution Studies in Cynomolgus Monkeys. Mo / . Imaging Bio / . 2016, 18, 768-775. M 264576 Anmeldetext.docx8. Shao, F.; Pan, Z.; Long, Y.; Zhu, Z.; Wang, K.; Ji, H.; Zhu, K.; Song, W.; Song, Y.; Song, X.; Gai, Y.; Liu, Q.; Qin, C.; Jiang, D.; Zhu, J. and Lan, X. Nectin-4- targeted immunoSPECT / CT imaging and photothermal therapy of triple-negative breast cancer. J. Nanobiotechno / ogy 2022, 20, 243. 9. Duan, X.; Xia, L.; Zhang, Z.; Ren, Y.; Pomper, M. G.; Rowe, S. P.; Li, X.; Li, N.; Zhang, N.; Zhu, H.; Yang, Z.; Sheng, X. and Yang, X. First-in-human study of the radioligand 68 Ga-N188 targeting nectin-4 for PET / CT imaging of advanced urothelial carcinoma. Clin. Cancer Res. 2023, DOI: 10.1158 / 1078-0432. CCR-23- 0609. 10. Zhang, J.; Duan, X.; Chen, X.; Zhang, Z.; Sun, H.; Shou, J.; Zhao, G.; Wang, J.; Ma, Y.; Yang, Y.; Tian, X.; Shen, Q.; Yu, W.; He, Z.; Fan, Y. and Yang, X. Translational PET imaging of Nectin-4 expression in multiple different cancers with 68 Ga-N188. J. Nucl. Med. 2024, 65, 12S-18S. 11. Wan, Q.; Yuan, H.; Cai, P.; Liu, Y.; Yan, T.; Wang, L.; Zhou, Z.; Zhang, W. and Liu, N. Effects of PEGylation on imaging contrast of 68 Ga-labeled bicyclic peptide PET probes targeting Nectin-4. Mol. Pharm. 2024, 21, 4430-4440. 12. Ge, S.; Jia, T.; Shi, J.; Cao, J.; Sang, S.; Li, J.; Zhang, B. and Deng, S. A cutting- edge 68 Ga-labeled bicyclic peptide PET molecular probe for noninvasive assessment of Nectin4 expression. Bioorg. Chem. 2024, 152, 107745. 13. Sun, L.; Sun, Y.; Zuo, K.; Fan, L.; Wang, X.; Zhang, J.; Hu, S.; Liu, X.; Li, J.; Li, Y.; Shao, Z.; Xu, X.; Wu, A. and Song, S. Pilot study of nectin-4-targeted PET imaging agent 68 Ga-FZ-NR-l in triple-negative breast cancer from bench to first- in-human. J. Nucl. Med. 2025, 66, 473-479. 14. Duan, X.; Zhang, Z.; Xu, H.; Zhang, J.; Yan, Y. and Yang, X. Preclinical evaluation of an A118F-radiolabeled bicyclic peptide targeting nectin-4. Mol. Pharm. 2025, 22, 221-228. 15. Grob, N. M.; Behe, M.; von Guggenberg, E.; Schibli, R. and Mindt, T. L. Meth- oxinine - an alternative stable amino acid substitute for oxidation-sensitive methionine in radiolabelled peptide conjugates. J. Pept. Sei. 2017, 23, 38-44. 16. Sihver, W.; Walther, M.; Ullrich, M.; Nitt-Weber, A. K.; Bohme, J.; Reissig, F.; Saager, M.; Zarschler, K.; Neuber, C.; Steinbach, J.; Kopka, K.; Pietzsch, H. J.; Wodtke, R. and Pietzsch, J. Cyclohexanediamine triazole (CHDT) M 264576 Anmeldetext.docxfunctionalization enables labeling of target molecules with Al 18 F / 68 Ga / 111 In. Bio- conjug. Chem. 2024, 35, 1402-1416. 17. Brandt, F.; Ullrich, M.; Laube, M.; Kopka, K.; Bachmann, M.; Löser, R.; Pietz- sch, J.; Pietzsch, H. J.; van den Hoff, J. and Wodtke, R. " Clickable" albumin bin- ders for modulating the tumor uptake of targeted radiopharmaceuticals. J. Med. Chem. 2022, 65, 710-733. 18. Nikolovska-Coleska, Z.; Wang, R.; Fang, X.; Pan, H.; Tomita, Y.; Li, P.; Roller, P. P.; Krajewski, K.; Saito, N. G.; Stuckey, J. A. and Wang, S. Development and optimization of a binding assay for the XIAP BIR3 domain using fluorescence polarization. Anal. Biochem. 2004, 332, 261-273. M 264576 Anmeldetext.docx
Claims
Patent claims 1. Compounds of general formula I (Formula I), where Y is; X is selected from the group consisting of O, Se and CH2; D 1-Naphthyl (Dl) or 2-Naphthyl (D2) is; L is selected from the group consisting of M 264576 Registration text.docx M 264576 Registration text.docx R 1 selected from the group consisting of H, F, Cl, Br, I, -CF3, -CH3, -OH and -OCH3; R 2 -OH or -NH2 is; Z CH or N is; M 264576 Registration text.docxm 0 or 1 is; n 0 or 1 is and p is an integer between 1 and 10.
2. Compound according to claim 1, wherein X = O or CH2.
3. Compound according to claim 1 or claim 2, wherein A is selected from the group consisting of Al, A2, A3, A6 and A9.
4. Compound according to any of the preceding claims, wherein L L2, L3 or is not present.
5. Compound according to one of the preceding claims, wherein m = 1 and D = Dl.
6. Compound according to any one of the preceding claims, wherein Y = Y2, X = O, A = Al.
7. Compound according to any one of the preceding claims, selected from the following: M 264576 Registration text.docx M 264576 Registration text.docx M 264576 Registration text.docx M 264576 Registration text.docx M 264576 Registration text.docx 8. Compound according to claim 1, wherein if A is A9, F [ 18 F]F' is, and if A is A10, I [ 123 I]I -, [ 124 I]I - , [ 125 I]I - , [ 131 I]I - is.
9. Complex comprising a compound according to claim 1, wherein A is Al to A8, and a radioactive metal ion or Al[ 18 F]F 2+ .
10. Complex according to claim 9, wherein the radioactive metal ion is selected from the group consisting of [ 61 Cu]Cu 2+ , [ 64 Cu]Cu 2+ , [ 67 Cu]Cu 2+ , [ 67 Ga]Ga 3+ , M 264576 Registration text.docx[ 68 Ga]Ga 3+ , [ 177 Lu]Lu 3+ , [ 149 [Tb]Tb 3+ , [ 155 [Tb]Tb 3+ , [ 152 [Tb]Tb 3+ , [ 161 [Tb]Tb 3+ , [ 225 Ac]Ac 3+ , [ 226 Ac]Ac 3+ , [ 132 La]La 3+ , [ 133 La]La 3+ , [ 135 La]La 3+ , [ 111 In]In 3+ , [ 86 Y]Y 3+ , [90 Y]Y 3+ , [ 212 Bi]Bi 3+ , [ 213 Bi]Bi 3+ , [ 43 Sc]Sc 3+ , [ 44 Sc]Sc 3+ , [ 203 Pb]Pb 3+ , [ 212 Pb]Pb 3+ consists.
11. Method for the preparation of compounds of general formula I, characterized in that a compound of general formula II (Formula II) wherein Y, X, D and m have the meanings specified in claim 1, using O-(7-azabenzotriazol-l-yl)-N, N, N', N'-tetramethyluronium hexafluorophosphate (HATU) to a compound of general formula III (Formula III) or a combination of the general formula IV (Formula IV) wherein L and A have the meanings specified in claim 1, M 264576 Registration text.docx is coupled.
12. Compound according to any one of claims 1 to 8 or complex according to any one of claims 9 or 10 for use as a medicinal product.
13. Compound according to any one of claims 1 to 8 or complex according to any one of claims 9 or 10 for use as a medicament for the diagnosis and treatment of diseases involving the cell surface protein Nectin-4.
14. Compound or complex according to claim 12 or claim 13, characterized in that the drug is a drug for the diagnosis and treatment of bladder cancer and breast cancer.
15. Use of compounds according to claims 1 to 7 in the manufacture of radiopharmaceuticals. M 264576 Registration text.docx
